Regulatory News
Date | Title | Link |
---|---|---|
March 28, 2024 | Appointment of Interim Chief Financial Officer | View article |
March 25, 2024 | First commercial adoption of Steriwave by the NHS | View article |
January 26, 2024 | Grant of Share Options | View article |
January 16, 2024 | Appointment of new Chief Financial Officer | View article |
Date | Title | Link |
---|---|---|
December 12, 2023 | TR-1: Notification of Major Holdings | View article |
December 11, 2023 | Result of Fundraising | View article |
December 5, 2023 | Result of Placing & Broker Option Update | View article |
December 4, 2023 | Close of Bookbuild | View article |
December 1, 2023 | Update Re investor-led financing | View article |
November 30, 2023 | Ondine Announces Investor-led Financing | View article |
November 16, 2023 | Photodisinfection Recommended as Standard of Care | View article |
September 25, 2023 | Half-year Report | View article |
August 21, 2023 | Issue of Equity and TVR | View article |
August 1, 2023 | Ondine commences first NHS Steriwave® pilot | View article |
July 7, 2023 | Corporate Update | View article |
May 25, 2023 | Result of AGM | View article |
May 23, 2023 | Annual Report for the Year Ended 31 December 2022 | View article |
May 10, 2023 | Full Year Results | View article |
May 3, 2023 | Notice of Results and Investor Presentation | View article |
May 3, 2023 | Notice of AGM | View article |
May 3, 2023 | Issue of Equity | View article |
April 17, 2023 | Progress Update | View article |
March 3, 2023 | Ottawa hospital presents Steriwave study results | View article |
February 22, 2023 | Grant of Share Options | View article |
January 31, 2023 | Ondine’s APDT reduces SARS-CoV-2 infectivity | View article |
January 17, 2023 | TR-1: Notification of major holdings | View article |
Date | Title | Link |
---|---|---|
December 30, 2022 | Appointment of Nominated Adviser | View article |
December 12, 2022 | Steriwave receives regulatory approval in Mexico | View article |
December 2, 2022 | Ondine reports full results from Phase 2 trial | View article |
November 4, 2022 | PDMR Dealing | View article |
October 28, 2022 | PDMR Dealing | View article |
October 19, 2022 | Steriwave™ cuts SSI risk by 47% at major hospital | View article |
September 27, 2022 | Interim results for the six months to 30 June 2022 | View article |
September 7, 2022 | Ondine’s photodisinfection kills ESKAPE pathogens | View article |
September 6, 2022 | Ondine reports successful US Phase 2 trial data | View article |
August 16, 2022 | Ondine appoints RBC and Singer as joint brokers | View article |
August 6, 2022 | Ondine completes US Phase II trial recruitment | View article |
July 26, 2022 | Completion of Nominated Adviser due diligence | View article |
July 22, 2022 | Issue of Equity | View article |
July 19, 2022 | Ondine completes successful SARS-CoV-2 trial | View article |
June 8, 2022 | Result of AGM | View article |
June 7, 2022 | Posting of Annual Report for the Year Ended 31 December 2021 | View article |
May 18, 2022 | Full Year Results to 31 December 2021 | View article |
May 17, 2022 | Notice of AGM | View article |
April 27, 2022 | Appointment of Nominated Adviser | View article |
February 21, 2022 | Grant of Options and PDMR Dealing | View article |
February 7, 2022 | Ondine treats first patients in Phase 2 FDA trial | View article |
Date | Title | Link |
---|---|---|
December 20, 2021 | Ondine and University of Navarra initiate clinical trial deploying nasal photodisinfection for a new variant-agnostic approach to stop SARS-CoV-2 replication in high-risk viral carriers | View article |
December 15, 2021 | Ondine Biomedical appoints Professor Trevor Jones to lead COVID-19 advisory board | View article |
December 6, 2021 | Ondine Biomedical announces AIM market listing | View article |